CDH22 Antibody

What are the key characteristics of CDH22 protein that researchers should understand?

CDH22 is a member of the cadherin superfamily characterized by:

• Five cadherin repeat domains and a cytoplasmic tail similar to classical cadherins

• Subcellular localization primarily in the cell membrane

• Involvement in brain development and cell adhesion mechanisms

• Post-translational modifications, particularly glycosylation

• Alternative names including cadherin 22 type 2, cadherin-like 22, ortholog of rat PB-cadherin, pituitary and brain cadherin, and PB-cadherin

The protein is predominantly expressed in the brain and may play crucial roles in morphogenesis and tissue formation in neural and non-neural cells during development and maintenance of the brain and neuroendocrine organs .

What are the primary applications for CDH22 antibodies in research?

CDH22 antibodies are employed in various experimental techniques including:

Western Blot is the most widely used application, with ELISA, Immunofluorescence, and Immunohistochemistry also being common approaches for CDH22 detection .

How should researchers choose between polyclonal and monoclonal CDH22 antibodies?

The choice depends on your experimental requirements:

Polyclonal CDH22 antibodies:

• Recognize multiple epitopes on the CDH22 protein

• Generally provide stronger signals due to multiple binding sites

• Useful for detecting proteins in denatured states (like Western blot)

• Available from multiple vendors with various target regions (N-terminal, central, etc.)

Monoclonal CDH22 antibodies:

• Target a single epitope with high specificity

• Provide more consistent results between batches

• Preferable for distinguishing between closely related proteins

• Useful in applications requiring minimal background

For initial characterization studies, polyclonal antibodies may provide better detection sensitivity, while monoclonal antibodies are preferable for studies requiring higher specificity or reproducibility between experiments.

What optimization strategies should researchers employ when using CDH22 antibodies in Western blot applications?

For optimal Western blot results with CDH22 antibodies:

• Sample preparation:

  • Use appropriate lysis buffers that preserve membrane proteins

  • Include protease inhibitors to prevent degradation of CDH22 (89.1 kDa)

  • Consider phosphatase inhibitors if investigating phosphorylation states

• Transfer optimization:

  • For this high molecular weight protein (89.1 kDa), use longer transfer times or semi-dry transfer systems

  • Consider using PVDF membranes rather than nitrocellulose for better protein retention

• Antibody dilution determination:

  • Test dilution ranges from 1:500-1:1000 as recommended by most suppliers

  • Perform titration experiments to determine optimal antibody concentration

• Blocking optimization:

  • Use 5% BSA in TBST rather than milk for reduced background

  • Test both BSA and milk to determine optimal blocking conditions

• Validation controls:

  • Include positive control samples (human brain tissue lysates)

  • Consider using CDH22 knockout or knockdown samples as negative controls

  • Look for the expected band at approximately 89.1 kDa

Case study data from manufacturer validation shows successful detection in cell lines including HepG2, 293, and K562 , which can serve as useful positive controls.

How should researchers approach CDH22 immunohistochemistry in brain tissue samples?

Brain tissue presents unique challenges for CDH22 immunohistochemistry:

• Tissue fixation and processing:

  • Use 10% neutral buffered formalin fixation (most validated antibodies are tested with FFPE samples)

  • Optimize antigen retrieval methods (heat-induced epitope retrieval with citrate buffer pH 6.0 is often effective)

• Antibody dilution and incubation:

  • Start with dilutions between 1:50-1:100 as recommended

  • Consider overnight incubation at 4°C to improve sensitivity

  • Use humidity chambers to prevent tissue drying

• Detection systems:

  • DAB staining systems work well with CDH22 antibodies

  • For fluorescent detection, consider FITC-conjugated antibodies for better visualization

• Controls and validation:

  • Include positive control tissues (human brain sections)

  • Use isotype controls to assess non-specific binding

  • Consider dual staining with neuronal markers to confirm cell-type specific expression

Manufacturer validation has demonstrated successful staining in human brain tissue with clear membrane localization patterns . When optimizing, focus on achieving clear membrane staining with minimal background in neural cells.

What experimental approaches are recommended for investigating CDH22's role in neural development?

To effectively study CDH22 in neural development:

• Expression analysis during development:

  • Use CDH22 antibodies for temporal expression profiling in developing brain tissue

  • Employ immunohistochemistry to map spatial distribution changes during development

  • Combine with neurodevelopmental markers for context

• Functional studies:

  • Use CDH22 antibodies to disrupt protein-protein interactions in primary neural cultures

  • Perform knockdown/knockout studies and use antibodies to confirm protein reduction

  • Consider calcium dependency experiments (as CDH22 is calcium-dependent)

• Interaction studies:

  • Immunoprecipitation with CDH22 antibodies to identify binding partners

  • Co-localization studies with other cadherins using immunofluorescence

  • Investigate interactions with known brain development pathways (like SLIT-ROBO signaling, referenced in the neuronal cadherin literature)

• Disease model investigations:

  • Use CDH22 antibodies to examine expression in neurodevelopmental disorders

  • Compare expression patterns between normal and pathological samples

  • Consider examining CDH22 in contexts similar to related cadherins associated with ASD (like CDH8, CDH9, CDH10, and CDH11)

Evidence suggests that cadherin family proteins play crucial roles in neurulation, neuronal proliferation, differentiation, migration, axon guidance, synaptogenesis, and synaptic maintenance , making these processes prime targets for CDH22 investigation.

How can researchers effectively validate CDH22 antibody specificity?

Thorough validation of CDH22 antibodies is critical for research reliability:

• Western blot validation:

  • Confirm single band at expected molecular weight (89.1 kDa)

  • Test in tissues with known CDH22 expression (brain) versus low-expressing tissues

  • Perform peptide competition assays using the immunizing peptide (e.g., synthetic peptide from amino acids 411-440 for central region antibodies)

• Genetic validation:

  • Test antibody in CDH22 knockout/knockdown models

  • Use siRNA-treated samples as negative controls

  • Consider testing in species with known CDH22 orthologs (mouse, rat, bovine, frog, chimpanzee, chicken)

• Orthogonal validation:

  • Compare results from antibodies targeting different epitopes of CDH22

  • Cross-validate findings using non-antibody methods (mRNA expression)

  • Compare antibodies from different vendors targeting the same region

• Cross-reactivity assessment:

  • Test against closely related cadherins

  • Evaluate specificity across multiple applications (WB, IHC, IF)

  • Check reactivity in samples from different species if working with non-human models

Specificity testing should include both positive controls (brain tissue) and negative controls (tissues with minimal CDH22 expression) to establish the detection range and limits.

What are the considerations when investigating CDH22 in neuropsychiatric disease models?

When studying CDH22 in neuropsychiatric contexts:

• Expression pattern analysis:

  • Compare CDH22 protein levels between control and disease samples

  • Examine potential alterations in subcellular localization

  • Investigate co-expression with disease-associated markers

• Genetic correlation:

  • Examine if CDH22 variants have been associated with neurodevelopmental disorders

  • Consider relationship with other cadherin family members linked to autism spectrum disorders (ASD)

  • Explore the CDH22 locus (20q13.12) for disease associations

• Functional implications:

  • Investigate cell adhesion properties in disease models

  • Examine potential alterations in neural circuit formation

  • Study effects on synaptogenesis and synaptic maintenance

• Experimental design:

  • Include age-matched and sex-matched controls

  • Consider developmental timing in analyses

  • Use multiple antibodies targeting different epitopes for validation

Research indicates that several cadherin family proteins (CDH8, CDH9, CDH10, CDH11, and CDH13) have been linked to autism spectrum disorders and ADHD , suggesting potential overlapping or compensatory functions that should be considered when investigating CDH22.

What protocols are recommended for studying CDH22 post-translational modifications?

To effectively study CDH22 post-translational modifications, particularly glycosylation :

• Sample preparation:

  • Use lysis buffers that preserve post-translational modifications

  • Consider phosphatase inhibitors to maintain phosphorylation states

  • Handle samples at 4°C to prevent enzymatic modifications

• Glycosylation analysis:

  • Treat samples with glycosidases (PNGase F for N-linked glycans)

  • Compare molecular weight shifts by Western blot

  • Use lectins alongside CDH22 antibodies for co-localization studies

• Phosphorylation studies:

  • Use phospho-specific antibodies if available

  • Perform phosphatase treatment as a control

  • Consider 2D gel electrophoresis to separate phosphorylated isoforms

• Other modifications:

  • Investigate proteolytic processing (similar to ADAM10-mediated cleavage seen in other cadherins)

  • Examine ubiquitination status for degradation studies

  • Consider mass spectrometry for comprehensive modification mapping

• Functional correlation:

  • Correlate modification patterns with cellular localization

  • Examine how modifications affect protein-protein interactions

  • Investigate modification changes during development or in disease states

Understanding these modifications is particularly important as evidence from related cadherins suggests that proteolytic processing can significantly impact function, as demonstrated by ADAM10-mediated cleavage of CDH2 .

How should researchers design experiments to distinguish CDH22 from other cadherin family members?

To effectively distinguish CDH22 from other cadherins:

• Antibody selection strategy:

  • Choose antibodies targeting unique regions of CDH22

  • Evaluate cross-reactivity with other cadherins, particularly closely related paralogs

  • Consider using antibodies against the less conserved regions (versus highly conserved cytoplasmic domains)

• Experimental controls:

  • Include expression controls for related cadherins (especially CDH7, an important paralog)

  • Perform parallel experiments with antibodies against multiple cadherin family members

  • Consider using tissues with differential expression of various cadherins

• Molecular approaches:

  • Use RT-PCR with CDH22-specific primers alongside antibody studies

  • Consider siRNA knockdown specific to CDH22 to confirm antibody specificity

  • Employ tagged expression constructs for overexpression studies

• Functional differentiation:

  • Design experiments to test CDH22-specific functions versus shared cadherin functions

  • Investigate calcium dependency at different concentrations

  • Examine specific protein-protein interactions unique to CDH22

The challenge of distinguishing between cadherin family members is significant, as the search results indicate there are multiple paralogs with potentially overlapping functions, particularly in neural tissues .

What are common troubleshooting approaches for weak or non-specific CDH22 antibody signals?

When encountering signal issues with CDH22 antibodies:

For membrane proteins like CDH22, consider:

• Using specialized lysis buffers designed for membrane proteins

• Avoiding freeze-thaw cycles that can degrade membrane proteins

• Optimizing antigen retrieval methods for IHC/IF applications

• Trying different fixation methods if performing ICC/IF

Most manufacturers recommend starting with the central region antibodies (amino acids 411-440) for optimal detection .

How can researchers effectively use CDH22 antibodies in co-immunoprecipitation studies?

For successful co-immunoprecipitation of CDH22:

• Lysis conditions:

  • Use non-denaturing lysis buffers to preserve protein-protein interactions

  • Include calcium in buffers (1-2 mM) to maintain cadherin-dependent interactions

  • Consider mild detergents like 1% NP-40 or 0.5% Triton X-100

  • Add protease and phosphatase inhibitors to preserve interactions

• Antibody selection:

  • Choose antibodies verified for immunoprecipitation applications

  • Consider using antibodies against different epitopes for confirmation

  • For pull-down, polyclonal antibodies often perform better than monoclonals

• Protocol optimization:

  • Pre-clear lysates to reduce non-specific binding

  • Optimize antibody-to-lysate ratios (typically 2-5 μg antibody per 500 μg protein)

  • Consider longer incubation times (overnight at 4°C) for complete binding

  • Use appropriate controls (IgG control, input control)

• Detection strategies:

  • Use clean detection antibodies from different species than the IP antibody

  • Consider trying sandwich ELISA approaches for quantification

  • For multiple interaction partners, consider mass spectrometry analysis

When investigating potential interaction partners, focus on proteins involved in brain development and cell adhesion pathways, as these are the primary functional areas for CDH22 .

What considerations should be made when selecting CDH22 antibodies for cross-species studies?

For cross-species applications with CDH22 antibodies:

• Species reactivity analysis:

  • Check manufacturer specifications for validated species (human, mouse, rat are most common)

  • Some antibodies show broader reactivity across species (bat, cow, dog, guinea pig, horse, monkey, pig, rabbit)

  • Consider sequence homology between target species for non-validated species

• Epitope conservation assessment:

  • Compare CDH22 sequence conservation at the antibody target region across species

  • Antibodies targeting highly conserved regions will have better cross-reactivity

  • N-terminal and central region antibodies may have different cross-reactivity profiles

• Validation approaches:

  • Test antibodies on known positive controls from target species

  • Perform parallel experiments with species-specific antibodies when available

  • Validate with orthogonal methods (RT-PCR with species-specific primers)

• Application considerations:

  • Western blot typically has better cross-reactivity than IHC/IF applications

  • Optimize application-specific conditions for each species

  • Consider higher antibody concentrations for less-reactive species

The search results indicate that CDH22 gene orthologs have been reported in mouse, rat, bovine, frog, chimpanzee, and chicken species , making these logical targets for cross-species studies.